Is PT-141 (Bremelanotide) Legal in Ohio?

The Short Answer on Ohio Legality

Bremelanotide is a legal pharmaceutical in Ohio when prescribed by a licensed clinician. The FDA's June 2019 approval of Vyleesi established it as a lawful prescription drug under federal law, and Ohio has enacted no independent statute that restricts it further. [1] Any Ohio resident with a valid prescription from an Ohio-licensed practitioner can fill that prescription at a licensed pharmacy.

The gray area arises with compounded versions, typically marketed as "PT-141 nasal spray", which are neither FDA-approved nor definitively authorized under current 503A compounding rules. That distinction matters and is covered in detail below.

Federal Law Sets the Baseline

The FDA approved bremelanotide injection 1.75 mg (Vyleesi, AMAG Pharmaceuticals) on June 21, 2019, under NDA 210557. [1] Federal law under the Food, Drug, and Cosmetic Act (FD&C Act) classifies bremelanotide as a prescription drug, not a controlled substance. The Drug Enforcement Administration has not scheduled it under the Controlled Substances Act, so neither a DEA registration nor a triplicate prescription form is required. [2]

Because bremelanotide is not controlled, practitioners in Ohio can prescribe it without the special DEA reporting obligations that apply to Schedule II or III drugs. Standard Ohio prescribing rules, a bona fide prescriber-patient relationship, a legitimate medical purpose, and documentation in a medical record, still apply.

Ohio Does Not Add Extra Restrictions

Ohio Revised Code (ORC) Chapter 4729 governs pharmacists and drug dispensing. ORC Chapter 4731 governs the practice of medicine. Neither chapter creates a bremelanotide-specific restriction beyond what federal law requires. [3] The Ohio State Board of Pharmacy enforces the federal legend-drug rule: bremelanotide may not be dispensed without a prescription, but with one, dispensing is lawful.

Ohio has also not placed bremelanotide on any state dangerous-drug or analog list, meaning the drug's legal category in Ohio mirrors its federal category: a non-controlled prescription legend drug.

FDA Approval: What Vyleesi Is (and Is Not)

The FDA approved Vyleesi specifically for premenopausal women with acquired, generalized HSDD. [1] Understanding the approved indication matters legally and clinically, because insurance coverage and compounding rules both hinge on it.

The Key Trial Data

Two Phase 3 trials (RECONNECT Study 1 and Study 2) formed the basis of FDA approval. Across the combined population of 1,247 women, bremelanotide produced a statistically significant improvement in the Female Sexual Function Index desire domain score versus placebo (P<0.001), along with a reduction in distress related to low sexual desire. [4] The studies used a 1.75 mg subcutaneous dose administered approximately 45 minutes before anticipated sexual activity.

The FDA's prescribing information explicitly states that Vyleesi is not approved for men, postmenopausal women, or women with HSDD caused by a medical or psychiatric condition or relationship problems. [1] Off-label prescribing for these groups is legally permissible under medical practice law, but those uses carry no FDA-backed safety data from key trials.

Mechanism and Scheduling Context

Bremelanotide is a melanocortin receptor agonist, specifically a non-selective agonist at MC1R, MC3R, MC4R, and MC5R. [5] Its action on MC4R in the central nervous system is thought to drive pro-sexual effects. Because the mechanism is central (CNS) rather than purely vascular (as with PDE5 inhibitors), there was initial regulatory concern about abuse potential. The FDA's review concluded that bremelanotide does not meet criteria for scheduling, given no evidence of reinforcing euphoric effects or recreational misuse patterns. [2]

Compounded PT-141 in Ohio: The Gray Area Explained

Most online discussion of "PT-141" refers not to branded Vyleesi but to compounded bremelanotide, frequently as a nasal spray or lyophilized powder for reconstitution. This is where Ohio residents face the most legal complexity.

503A Compounding Pharmacies

Under Section 503A of the FD&C Act, a state-licensed compounding pharmacy can prepare a drug product for an individual patient when a valid prescription is presented, provided the drug is not a "essentially a copy" of a commercially available product and the bulk active ingredient meets USP or NF standards. [6] The FDA maintains a list of bulk drug substances that may or may not be used in 503A compounding.

Bremelanotide has been nominated to FDA's 503A Bulks List (Category 2, substances nominated but for which FDA has not yet made a final determination). [7] As of mid-2025, the FDA has neither formally authorized nor formally prohibited bulk bremelanotide for 503A compounding. This means compounding pharmacies that prepare it are operating in a regulatory gray zone, technically not prohibited by a final FDA order, but also without explicit authorization.

Ohio pharmacies that compound bremelanotide without final FDA authorization do so at regulatory risk, particularly because a branded FDA-approved product (Vyleesi) already exists. The FDA's "essentially a copy" prohibition under 503A could apply. [6]

503B Outsourcing Facilities

503B outsourcing facilities produce drugs in bulk without patient-specific prescriptions and are subject to FDA inspection and cGMP requirements. [8] The same 503A Bulks List ambiguity applies to 503B facilities for bremelanotide. No 503B outsourcer has received formal FDA authorization to compound bremelanotide as of this writing.

Nasal Spray Formulations

The compounded nasal spray version of PT-141 is particularly problematic from a regulatory standpoint. Vyleesi is an injectable; a nasal spray is a different route of administration and a different drug product. The FDA has not approved any nasal bremelanotide product. [1] Under current FDA policy, compounding a drug in a dosage form that differs significantly from the approved product requires specific clinical justification documented in the prescription. Ohio pharmacists who fill such prescriptions without that documentation may face board scrutiny.

The table below summarizes the legal status by product type for Ohio residents:

| Product Type | Legal in Ohio? | Notes | |---|---|---| | Vyleesi 1.75 mg SC (branded) | Yes, with valid Rx | FDA-approved; fill at any licensed Ohio pharmacy | | Compounded injectable bremelanotide | Gray area | 503A Bulks List Category 2; "essentially a copy" concern | | Compounded nasal spray PT-141 | Gray area / higher risk | Different dosage form; no FDA approval; needs clinical justification | | Research-chemical PT-141 (no Rx) | Not authorized | Selling as drug without approval violates FD&C Act | | PT-141 purchased online without Rx | Not legal | Federal legend-drug rule applies in Ohio |

How to Get a Legal PT-141 Prescription in Ohio

Ohio residents have three main pathways to a legal bremelanotide prescription: an in-person visit to a women's health or sexual medicine specialist, a referral from a primary care physician, or a telehealth consultation with an Ohio-licensed provider.

In-Person Specialists

Sexual medicine clinics, gynecologists, and urologists are the most common prescribers of bremelanotide in Ohio. The American College of Obstetricians and Gynecologists (ACOG) published Committee Opinion 780, which addresses low sexual desire in women and references approved pharmacological options including bremelanotide. [9] A gynecologist familiar with ACOG guidance is well-positioned to evaluate HSDD and prescribe Vyleesi when appropriate.

The North American Menopause Society (NAMS) 2022 position statement on sexual health notes that bremelanotide is one of two FDA-approved pharmacological treatments for HSDD (the other being flibanserin). [10] NAMS states: "Bremelanotide 1.75 mg subcutaneous injection has demonstrated efficacy in premenopausal women with generalized HSDD." [10]

Telehealth in Ohio

Ohio House Bill 197 (2020) and subsequent regulatory guidance from the State Medical Board of Ohio permit synchronous telemedicine visits as the basis for a valid prescriber-patient relationship, provided the prescriber holds an active Ohio medical license. A telehealth consultation via audio-video is legally sufficient to establish a prescribing relationship for a non-controlled drug like bremelanotide. [3]

Asynchronous ("store-and-forward") telehealth, where a patient fills out a questionnaire with no live interaction, occupies a more ambiguous position under Ohio Board guidance for initiating new prescriptions. Clinicians using asynchronous-only platforms for bremelanotide prescribing should ensure their platform complies with current State Medical Board of Ohio standards.

What the Clinical Evaluation Should Include

A prescriber evaluating a patient for bremelanotide in Ohio should, at minimum:

• Confirm premenopausal status (or document clinical justification for off-label use)
• Screen for HSDD using a validated tool such as the Female Sexual Distress Scale-Revised (FSDS-R) or the DESIRE scale
• Rule out relationship or psychiatric causes of low desire
• Review cardiovascular history (bremelanotide causes transient blood pressure increases; mean systolic increase of approximately 6 mmHg post-dose) [4]
• Confirm no concomitant use of naltrexone, which substantially reduces bremelanotide exposure via pharmacokinetic interaction [1]

The FDA label warns that bremelanotide should not be used in patients with cardiovascular disease, given the transient hypertensive effect. [1] This is not an Ohio-specific rule, it applies nationally, but Ohio providers should document this screening in the medical record.

Dosing, Administration, and Safety Profile

Vyleesi comes as a single-dose auto-injector (1.75 mg/0.3 mL). The patient injects subcutaneously into the abdomen or thigh approximately 45 minutes before sexual activity. [1] No more than one dose in 24 hours is recommended, and the FDA label recommends against more than one dose per day and no more than one dose in any 24-hour period.

Common Adverse Effects

In the RECONNECT trials (N=1,247), the most common adverse effects were: [4]

• Nausea: 40% (bremelanotide) vs. 1% (placebo)
• Flushing: 20% vs. 2%
• Injection-site reactions: 13% vs. 5%
• Headache: 11% vs. 4%
• Transient hyperpigmentation (focal): reported in approximately 1% of patients with extended use

Nausea was the primary driver of discontinuation in trial data; approximately 13% of bremelanotide-treated patients withdrew due to adverse events versus 2% of placebo patients. [4] A 4 mg oral ondansetron dose taken 1 hour before bremelanotide administration reduced nausea incidence in clinical practice, though this co-administration is not part of the FDA-approved label. [5]

Drug Interactions

The FDA label identifies one clinically significant drug interaction: naltrexone. Co-administration decreases bremelanotide AUC by approximately 35%. [1] Patients on naltrexone for opioid use disorder or alcohol use disorder should not be prescribed bremelanotide without consideration of this interaction. There are no known interactions with oral contraceptives, selective serotonin reuptake inhibitors, or common antihypertensives in the prescribing information. [1]

Off-Label Use: Male Sexual Dysfunction

A meaningful portion of demand for PT-141 comes from men seeking treatment for erectile dysfunction or low libido. The FDA has not approved bremelanotide for any indication in men. [1] Off-label prescribing for men is legal under both federal and Ohio law, physicians may prescribe approved drugs for unapproved uses when clinical judgment supports it.

Small clinical studies suggest bremelanotide may produce pro-erectile effects via central MC4R agonism. A Phase 2 dose-escalation study published in the Journal of Sexual Medicine (N=103 men with ED) found improvements in erectile function scores at doses of 0.025 mg/kg and 0.050 mg/kg subcutaneous. [11] That study used weight-based dosing rather than the fixed 1.75 mg dose in Vyleesi, and was conducted before FDA approval. No Phase 3 trial in men has been completed or submitted for FDA review.

Ohio urologists and men's health clinicians who prescribe bremelanotide off-label for male patients should document the clinical rationale, discuss the absence of Phase 3 efficacy data, and obtain informed consent specifically noting the off-label nature of the prescription.

Ohio State Board of Pharmacy: Dispensing Rules

The Ohio State Board of Pharmacy enforces ORC 4729 and corresponding administrative code sections. For bremelanotide specifically:

Legend Drug Requirements

Bremelanotide carries an Rx-only designation under federal law. Ohio pharmacies must verify a valid prescription, prescriber name, DEA number if applicable (not required for non-controlled), patient name, date, quantity, directions, before dispensing. [3] No special Ohio permit is required beyond a standard pharmacy license to dispense Vyleesi.

Compounding Oversight

Ohio-licensed compounding pharmacies that wish to compound bremelanotide must operate within both federal 503A guidelines and Ohio Board of Pharmacy rules in OAC 4729-16. [3] Given the FDA's Category 2 status for bulk bremelanotide, a prudent Ohio compounding pharmacist should obtain written confirmation from their legal counsel or the Ohio Board of Pharmacy before preparing the drug. The Board has authority to take disciplinary action against pharmacies that compound drugs in ways that violate federal law. [3]

Research Chemical PT-141: Why It Is Not a Legal Option

Some websites sell PT-141 as a "research chemical" or "for laboratory use only" with no prescription required. This is not a legal pathway for human use in Ohio or any other state. Under the FD&C Act, bremelanotide is a drug (it is intended to affect the structure or function of the body), and marketing it for human consumption without an approved NDA or valid prescription violates federal law. [12] The FDA has issued multiple warning letters to companies selling peptides in this category. [12] Purchasing from these sources also carries unknown purity and potency risks, since such products are not manufactured under cGMP standards.

The Ohio Board of Pharmacy and the Ohio State Medical Board both have authority to pursue action against practitioners or facilities that direct patients to unregulated peptide sources.

Insurance Coverage and Cost in Ohio

Vyleesi is FDA-approved but coverage on Ohio insurance formularies is inconsistent. Most major Ohio commercial plans (Medical Mutual, Anthem, UnitedHealthcare Ohio) have historically placed bremelanotide on Tier 4 or excluded it entirely, based on formulary reviews available through each plan's published drug list. [13] Ohio Medicaid does not currently list bremelanotide as a covered drug.

The list price of Vyleesi is approximately $950 per auto-injector (one dose) without insurance. AMAG Pharmaceuticals (now acquired by Covis Pharma) has offered a manufacturer savings card reducing out-of-pocket cost to $99 per month for commercially insured patients who qualify. [13] Patients should verify current card availability directly with Covis Pharma.

Summary of Legal Status by Use Case

Ohio residents considering bremelanotide fall into one of these scenarios:

Scenario 1, Premenopausal woman with HSDD, Vyleesi prescribed. Fully legal. Fill at any Ohio-licensed pharmacy.

Scenario 2, Any patient, compounded injectable bremelanotide prescribed. Gray area under 503A. Legal risk exists for both compounding pharmacy and prescriber; patients should ask their provider to document clinical justification.

Scenario 3, Any patient, compounded nasal spray PT-141 prescribed. Higher regulatory risk. No FDA approval for this route; requires strong clinical justification documented in the prescription.

Scenario 4, PT-141 purchased online without a prescription. Not legal under federal or Ohio law.

Scenario 5, Off-label use in men, prescribed by licensed Ohio physician. Legal. Document clinical rationale and informed consent.